References
- Albino, R. (1997). Multidrug resistant tuberculosis. Current Opinion in Infectious Diseases, 10(2), 116–122. https://doi.org/10.1097/00001432-199704000-00009
- Bajehson, M. G. (2019). Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria. PLoS ONE, 14(11), 4–6, e0225165. https://doi.org/10.1371/journal.pone.0225165.
- Balaji, D. A. (2010). Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One, 5(3), 2-4. https://doi.org/10.1371/journal.pone.0009527
- Beauchamp, T. L., & Childress, J. F. (2001). Principles of biomedical ethics (5th ed.). Oxford University Press.
- Cartolovni, S. S. (2021). Moral injury in healthcare professionals: A scoping review and discussion. Nursing Ethics, 595. https://doi.org/10.1177/0969733020966776.
- Christman, J. (2020, June 29). Autonomy in Moral and Political Philosophy. The Stanford Encyclopedia of Philosophy (Fall 2020 Edition).
- Cookson, D. (2000). Principles of justice in health care rationing. Journal of Medical Ethics, 26(5), 323–329. https://doi.org/10.1136/jme.26.5.323
- Degeling, C. (2015). The political and ethical challenges of multi-drug resistant tuberculosis. Journal of Bioethical Inquiry, 12(1), 107–113. https://doi.org/10.1007/s11673-014-9595-3
- Emanuel, E. J., & Wetheimer, A. (2006). Who should get influenza vaccine when not all can? Science, 312(5775), 854–855. https://doi.org/10.1126/science.1125347.
- Faustini, H. P. (2006). Risk factors for multidrug resistant tuberculosis in Europe: A systematic review. Thorax, 61(2), 158–163. https://doi.org/10.1136/thx.2005.045963
- Formosa, P. (2014). Dignity and respect: How to apply Kant’s formula of humanity. The Philosophical Forum, 45(1), 49–68. https://doi.org/10.1111/phil.12026
- Hill T. E. (1980). Humanity as an end in itself. The University of Chicago Press, 91(1), 84–99. https://doi.org/10.1086/292205
- Holm, S. (2012). Book review: Principles of Biomedical Ethics. Journal of Medical Ethics, 28(5), 332–332. https://doi.org/10.1136/jme.28.5.332–a
- Kant, I., Bennett, C., Saunders, J., & Stern, R. (2019) Groundwork of the metaphysics of morals (Vol. 4, pp. 435). London, England: Oxford University Press.
- Kass, N. (2001). An ethics framework for public health. American Journal of Public Health, 91(11), 1776–1782. https://doi.org/10.2105/AJPH.91.11.1776
- Lee, M. (2012). Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New England Journal of Medicine, 367(16), 1508–1518. https://doi.org/10.1056/NEJMoa1201964
- Orenstein, E. (2009). Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. The Lancet Infectious Diseases, 9(3), 153–161. https://doi.org/10.1016/S1473-3099(09)70041-6
- Persad, W. E. (2009). Principles for allocation of scarce medical interventions. The Lancet, 373(9661), 423–431. https://doi.org/10.1016/S0140-6736(09)60137-9.
- Pooran, P. D., Pieterson, E., Davids, M., Theron, G., & Dheda, K. (2013). What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE, 8(1), 6–8. https://doi.org/10.1371/journal.pone.0054587
- Queensland Health. (2021). Treatment of tuberculosis in adults and children - Guideline Version 3.0. Communicable Diseases Branch, Department of Health, Queensland Health, 7-8. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0029/444566/tb-guideline-treatment.pdf.
- Selgelid, R. (2011). Ethical issues in tuberculosis diagnosis and treatment. The International Journal of Tuberculosis and Lung Disease, 15(6), 9–13. https://doi.org/10.5588/ijtld.10.0434
- Seung, K. R. (2015). Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harbor Perspectives in Medicine, 5(9), a017863. https://doi.org/10.1101/cshperspect.a017863
- Shay, J. (1995). Achilles in Vietnam: Combat trauma and the undoing of character. Simon & Schuster.
- TB India. (2008). RNTCP Status Report. National TB Control Program of India. In: Faustini et al, 2006.
- WHO. (1978). Declaration of Alma-Ata. International Conference on Primary Health Care. http://www.who.int/publications/almaata_declaration_en.pdf.
- WHO. (2011a). The new WHO report on anti-tuberculosis drug resistance - multidrug and extensively drug-resistant TB: Global report in surveillance and response.
- WHO. (2011b). Standards and operational guidance for ethics review of health-related research with human participants.
- WHO. (2017). Ethics guidance for the implementation of the End TB strategy.
- WHO. (2020, October 14). TB Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/tuberculosis.
- World Health Organization. (1999). What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. Geneva, Switzerland: Communicable Disease Cluster, Prevention and Control, World Health Organization.
- Yadav, P. (2012). Confronting challenges to the supply chain of second-line drugs. In D. Behera & V. M. Katoch (Eds.), Facing the reality of drug-resistant tuberculosis in India: Challenges and Potential Solutions: Summary of a Joint Workshop (pp. 99–111). Washington, DC: National Academies Press (US).
![Supercharge Your Next Research Paper: Research and write your next paper with Jenni AI.]({"type":"image" , "src" : "/sda/112443/Skyscraper-socialsciences.png"})